SOLID BIOSCIENCES INC
SLDBNASDAQTrading Snapshot
- Day Range
- $7.05 – $7.25
- 52-Week Range
- $3.79 – $11.45
- Volume
- $2.15B
- Avg Volume
- $1.61B
- Shares Outstanding
- 98.4M
- Next Earnings
- Nov 9, 2026
Fundamentals Snapshot
- Annual Revenue
- $55M
- Last Q Revenue
- $13M
- P/E Ratio
- -3.8
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.44
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +76.8%
Why Investors Own SLDB
- ✓High-growth profile — revenue up +54.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 65% gross margin and 25% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
SOLID BIOSCIENCES INC
SLDB
StockOtter · stockotter.spaceAbout SOLID BIOSCIENCES INC
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Solid Biosciences: A Funded Challenge To Duchenne Gene Therapy's Limitations
Solid Biosciences is a speculative buy, leveraging a differentiated SGT-003 gene therapy for Duchenne muscular dystrophy with a credible cash runway into mid-2028. SLDB's investment thesis centers on building both biolog
Solid Biosciences Inc. (SLDB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Solid Biosciences Inc. (SLDB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Solid Biosciences to Participate at Upcoming Investor Conferences
CHARLESTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseas
Solid Biosciences: The Bull Case Is No Longer Just Duchenne
Solid Biosciences is transitioning from a speculative Duchenne gene therapy play to a multi-asset rare disease platform with clinical validation momentum. SLDB's $380.7M cash position funds operations into 2028, supporti